Orexo
Develops pharmaceuticals and digital therapies for substance use and mental health.
ORX | ST
Overview
Corporate Details
- ISIN(s):
- SE0000736415 (+2 more)
- LEI:
- 549300LJ5CCWDPTK9Z08
- Country:
- Sweden
- Address:
- Box 303, 751 05 UPPSALA
- Website:
- https://orexo.com/
- Sector:
- Manufacturing
Description
Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2013-01-31 07:57 | Swedish | 1.1 MB | |||
| 2013-01-31 07:57 | English | 1.2 MB | |||
| 2013-01-25 08:37 |
Orexo enters research agreement with AstraZeneca for respiratory disease program
|
English | 42.5 KB | ||
| 2013-01-25 08:37 |
Orexo ingår forskningsavtal med AstraZeneca inom området luftvägssjukdomar
|
Swedish | 26.6 KB | ||
| 2012-12-28 15:58 |
Antal aktier och röster i Orexo
|
Swedish | 85.0 KB | ||
| 2012-12-28 15:58 |
Number of shares and votes in Orexo
|
English | 85.4 KB | ||
| 2012-12-19 09:58 |
Orexo provides US commercialization progress update and direction for 2013 fina…
|
English | 175.1 KB | ||
| 2012-12-19 09:58 |
Orexo uppdaterar om kommersialiseringsplaner i USA och lämnar en bedömning av f…
|
Swedish | 178.0 KB | ||
| 2012-11-30 16:28 |
Antal aktier och röster i Orexo
|
Swedish | 23.6 KB | ||
| 2012-11-30 16:28 |
Number of shares and votes in Orexo
|
English | 27.2 KB | ||
| 2012-11-28 07:58 |
New study by Orexo emphasizes importance of Zubsolv™ product characteristics in…
|
English | 199.2 KB | ||
| 2012-11-28 07:58 |
Orexos nya studie tydliggör betydelsen av produktegenskaper hos Zubsolv™ jämför…
|
Swedish | 195.4 KB | ||
| 2012-11-19 07:58 |
Orexo meddelar att Zubsolv™ nu accepterats för granskning av den amerikanska lä…
|
Swedish | 94.4 KB | ||
| 2012-11-19 07:58 |
Orexo announces that Zubsolv™ has been accepted for review by the U.S. Food and…
|
English | 96.2 KB | ||
| 2012-11-13 08:15 |
Orexo announces submission of a New Drug Application for KW-2246 (Abstral®) in …
|
English | 96.3 KB |
Automate Your Workflow. Get a real-time feed of all Orexo filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Orexo
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Orexo via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-11 | Nikolaj Arrild Sørensen | Other | Buy | 2,460 | 35,178.00 SEK |
| 2025-04-04 | Nikolaj Arrild Sørensen | Other | Buy | 3,500 | 47,530.00 SEK |
| 2024-03-26 | Fredrik Järrsten | Other | Buy | 3,000 | 44,040.00 SEK |
| 2023-11-24 | Charlotte Vithlani Hansson | Other | Buy | 3,000 | 44,640.00 SEK |
| 2023-11-08 | Fredrik Järrsten | Other | Buy | 1,500 | 23,715.00 SEK |
| 2023-02-24 | Nikolaj Arrild Sørensen | Other | Buy | 11,500 | 188,945.00 SEK |
| 2023-01-27 | Fredrik Järrsten | Other | Buy | 4,500 | 79,695.00 SEK |
| 2022-07-26 | Michael Matly | Other | Buy | 2,820 | 60,777.77 SEK |
| 2022-07-21 | Charlotte Vithlani Hansson | Other | Buy | 3,000 | 61,500.00 SEK |
| 2022-07-15 | James Noble | Other | Buy | 18,500 | 394,252.80 SEK |
Peer Companies
